

Public Health Consequences of Use of Antimicrobial Agents in Food Animals in the United States

ALICIA D. ANDERSON, JENNIFER M. NELSON, SHANNON ROSSITER,
and FREDERICK J. ANGULO

ABSTRACT

The use of antimicrobial agents in food animals has caused concern regarding the impact these uses have on human health. Use of antimicrobial agents in animals and humans results in the emergence and dissemination of resistant bacteria. Resistant bacteria from food animals may be passed through the food chain to humans resulting in resistant infections. Increasing resistance to antimicrobial agents that are important in the treatment of human diseases, such as fluoroquinolones and third-generation cephalosporins for the treatment of *Salmonella* and *Campylobacter* infections, has significant public health implications. Efforts to mitigate the effects of increasing resistance require collaboration by several partners, including the farming, veterinary, medical, and public health communities.

INTRODUCTION

ANTIMICROBIAL AGENTS have been used in livestock and poultry since the early 1950s to treat infections and improve growth and feed efficiency. The amount of antimicrobial agents used in food animals (cattle, chickens, pigs, and turkeys) in the United States is unknown; however, a substantial portion given to these animals is for nontherapeutic uses (*i.e.*, uses in the absence of disease) such as growth promotion, a practice that is becoming increasingly controversial. The use of antimicrobial agents in food animals that have a human analog increases the likelihood that bacterial pathogens that have food animal reservoirs will develop cross-resistance to antimicrobial agents used in human medicine. The World Health Organization, following a series of consultations in 1997, 1999, and 2000, has recommended that, unless a risk-based evaluation demonstrates their safety, the use of antimicrobial agents in food animals for growth promotion that belong to classes of antimicrobial agents used in humans should be terminated.⁶⁴⁻⁶⁶ Similar recommendations to discontinue the use of human antimicrobial agents as growth promoters in food animals have been made by several independent organizations in the United States, including the Alliance of Prudent Use of Antibiotics in 2002²¹ and the distinguished Institute of Medicine of the National Academies in 2003.³⁰

Several European countries have already taken steps toward this goal. In 1998, the European Union banned four growth promoters (tylosin, spiramycin, bacitracin, and virginiamycin) because of their structural relatedness to antimicrobial agents used in human medicine.¹⁴ In that same year, chicken farmers and beef producers in Denmark voluntarily stopped using antimicrobial agents as growth promoters; swine farmers followed suit in 1999. This ban has reduced the total volume of antimicrobial agents used in food animals in Denmark by 60% (from 206 to 81 tons per year).^{17,52} Studies to investigate the influence of the ban have shown no negative consequence for farmers' profits or animal health in broiler chickens.²⁰ Similar conclusions were reported in fattening pigs, although diarrhea in weaned piglets has required other interventions, such as improved feeding and weaning procedures.⁵² In Sweden, antimicrobial agents were banned as growth promoters in 1986, decreasing the usage of antimicrobial agents in food animals by 55% and demonstrating the ability to achieve competitive production results in the absence of growth promotants.^{27,60} The effects of discontinuation of antimicrobial agents as growth promoters in these European countries have been a decrease in antibiotic resistance in animals, food products, and humans.^{1,6,17,33,45,58}

Clinicians should be aware that antimicrobial resistance is increasing in foodborne pathogens such as *Salmonella* and *Campylobacter* and that patients who are taking antimicrobial

agents for any reason are at increased risk for acquiring antimicrobial-resistant foodborne infections. The increasing prevalence of antimicrobial resistance among these pathogens also increases the potential for treatment failures and other adverse outcomes, including death. Appropriate use of antimicrobial agents in humans and food animals is necessary to maintain their effectiveness and reduce the potential for spread of resistant organisms. While therapeutic usage of antimicrobial agents in food animals is important for promoting animal health, it is vital that the long-term effectiveness of antimicrobial agents used in human medicine be preserved. This report presents current surveillance information on the frequency of resistant foodborne infections in the United States, reviews scientific evidence linking antimicrobial agent usage in food animals to resistant foodborne infections in humans, and makes recommendations for measures to protect public health.

USE OF ANTIMICROBIAL AGENTS IN FOOD ANIMALS IN THE UNITED STATES

At least 17 classes of antimicrobial agents are approved for growth promotion and feed efficiency in the United States, including tetracyclines, penicillins, macrolides, lincomycin (analog of clindamycin), and virginiamycin (analog of quinupristin/dalfopristin). To understand the human health consequences of the use of antimicrobial agents in food animals, it is important to evaluate the quantity of antimicrobial agents used in food animals in the United States. Unfortunately, although reporting systems recently have been implemented in several European countries, no reporting system exists for the quantity of antimicrobial agents used in food animals in the United States. The Animal Health Institute, which reportedly represents 80% of the companies that produce antimicrobial agents for animals in the United States, has estimated that their member companies produced 18 million pounds of antimicrobial agents for therapeutic and nontherapeutic (growth promotion and disease prevention) use in food animals in the United States in 1999.⁵ An alternative report, provided by the Union of Concerned Scientists in 2001, estimated that 29 million pounds of antimicrobial agents are used in food animals annually in the United States of which 25 million pounds are used for nontherapeutic purposes.³⁹ Although more precise data on the quantity of antimicrobial agents used in food animals is needed, these initial estimates provide some perspective on the quantity of antimicrobial agents used in food animals in the United States.

As in human medicine, the use of antimicrobial agents in food animals creates a selective pressure for the emergence and dissemination of antimicrobial-resistant bacteria, including animal pathogens, human pathogens that have food animal reservoirs, and other bacteria that are present in food animals.^{13,36,57} These resistant bacteria may be transferred to humans either through the food supply or by direct contact with animals.^{32,36,44,63} The transfer of resistant bacteria from food animals to humans is most evident in human bacterial pathogens that have food animal sources, such as *Campylobacter*, which has a reservoir in chickens and turkeys,^{2,55,56} and *Salmonella*, which has reservoirs in cattle, chickens, pigs, and turkeys.^{4,40} To monitor antimicrobial resistance in foodborne enteric

pathogens, the National Antimicrobial Resistance Monitoring System (NARMS) for Enteric Bacteria was launched in 1996.

NARMS is a collaboration among the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA)—Center for Veterinary Medicine, the United States Department of Agriculture (USDA), and state and local health departments (<http://www.cdc.gov/narms>). In addition to NARMS, the Foodborne Diseases Active Surveillance Network (FoodNet) conducts population-based studies to estimate the burden and sources of specific foodborne diseases in nine states (<http://www.cdc.gov/foodnet>).

Campylobacter

Campylobacter species typically cause mild to moderate infections but occasionally can cause severe infections, particularly in infants, elderly, or immunocompromised persons. Antimicrobial agents are usually not essential in the treatment of *Campylobacter* infections, but may be life-saving in the case of severe infections. Fluoroquinolones (*i.e.*, ciprofloxacin) are commonly used in the treatment of adults with acute gastroenteritis, including patients with *Campylobacter* infections.

NARMS has been used to monitor the prevalence of fluoroquinolone-resistant *Campylobacter* in the United States since 1997. The emergence of fluoroquinolone resistance among *Campylobacter* is an example of antimicrobial resistance resulting from the use of antimicrobial agents in food animals and the subsequent transfer via the food supply of resistant bacteria to humans. Fluoroquinolones were approved for human medicine in 1986. A national prospective study of reported *Campylobacter* cases between 1989 and 1990 found no *Campylobacter jejuni* isolates to be resistant to fluoroquinolones.¹⁰ The first fluoroquinolones approved for use in food animals in the United States were sarafloxacin in 1995 and enrofloxacin in 1996. These fluoroquinolones were approved for the treatment of respiratory disease in chickens and turkeys. A study conducted in Minnesota reported that resistance of human *Campylobacter jejuni* infections to nalidixic acid, an elementary quinolone, increased from 1% in 1992 to 10% in 1998; among *Campylobacter* isolates, there is a close correlation between isolates that are resistant to nalidixic acid and isolates that are resistant to fluoroquinolones. Nalidixic acid-resistant infections that were domestically acquired increased significantly from 1996 through 1998, a finding that was temporally associated with the licensure of fluoroquinolones for use in poultry in 1995. Molecular subtyping of human isolates and domestic chicken products from retail stores in Minnesota showed a significant association between resistant *Campylobacter jejuni* strains from chickens and domestically acquired infections in residents.⁵¹ Testing of 1997 NARMS *Campylobacter jejuni* isolates at CDC found fluoroquinolone resistance among 12% of the isolates; this prevalence increased to 18% of isolates in 2001.¹¹

In a case-control study of fluoroquinolone-resistant *Campylobacter* infections conducted in the FoodNet sites, 58% of resistant infections were acquired domestically (Kassenborg *et al.*, unpublished data). When domestically acquired fluoroquinolone-resistant *Campylobacter* cases were compared with well controls, cases were 10 times more likely to have eaten poultry cooked at a commercial establishment. Because chicken

is not imported into the United States, this observation supports the conclusion that poultry is the dominant source of domestically acquired fluoroquinolone-resistant *Campylobacter* infections in the United States. In a recent risk assessment, the FDA concluded that the use of fluoroquinolones in chickens in the United States has compromised the treatment with fluoroquinolones of almost 10,000 people a year; meaning that each year, thousands of people with *Campylobacter* infections seek medical care and are treated with fluoroquinolones, but their infection is already fluoroquinolone resistant.²⁴

Salmonella

In addition to fluoroquinolone-resistant *Campylobacter*, there is also the potential for an emergence of domestically acquired fluoroquinolone-resistant *Salmonella* in the United States. Antimicrobial agents are commonly used empirically for treatment of patients with *Salmonella* infections and may be life-saving for persons with invasive infections. Fluoroquinolones are the most commonly used antimicrobial agent for the treatment of invasive *Salmonella* infections in adults.⁴ Although few non-Typhi *Salmonella* isolates in NARMS from 1996 to 2001 were resistant to fluoroquinolones (MIC ≥ 4 $\mu\text{g/ml}$), 1% of isolates in 2001 had a decreased susceptibility to fluoroquinolones (MIC ≥ 0.25 $\mu\text{g/ml}$), an increase from 0.4% in 1996.¹¹ *Salmonella* isolates with decreased susceptibility to fluoroquinolones (but that are not resistant to fluoroquinolones) commonly have a single point mutation in a chromosomal gene.¹⁶ *Salmonella* isolates with decreased susceptibility to fluoroquinolones are of immediate concern because such isolates typically only require a single additional point mutation to become resistant and therefore represent a potential reservoir for the emergence of resistant *Salmonella* should such isolates be exposed to continued selective pressure.³⁴ Furthermore, patients infected with *Salmonella* strains with a decreased susceptibility to fluoroquinolones may respond poorly to treatment with fluoroquinolones and have been associated with apparent treatment failures.^{16,41}

Third-generation cephalosporins, such as ceftriaxone, are commonly used for treatment of invasive *Salmonella* infections in children because of their pharmacodynamic properties and low prevalence of resistance to these agents. Therefore, there is concern about the potential emergence of ceftriaxone-resistant *Salmonella*. The first reported case of domestically acquired ceftriaxone-resistant *Salmonella* was in a 12-year-old child in Nebraska.²² Investigation by public health officials revealed that the child lived on a farm and his father was a veterinarian. Before the child's illness, the father was treating several cattle herds for outbreaks due to culture-confirmed *Salmonella* infection. Although no information was available regarding the use of antimicrobial agents among the infected herds, a third-generation cephalosporin, ceftiofur, is widely used in cattle. Ceftriaxone-susceptible and ceftriaxone-resistant *Salmonella* were isolated from ill cattle treated by the veterinarian. Both ceftriaxone-resistant and ceftriaxone-susceptible cattle isolates and the ceftriaxone-resistant isolate from the child had similar genetic structures as determined by pulsed-field gel electrophoresis (PFGE). These similar molecular "fingerprints" and their temporal isolation suggest that ceftriaxone resistance emerged in the cattle herds, probably following use of ceftio-

fur or other antibiotics that would have selected for and maintained the ceftriaxone-resistant determinant within the intestinal flora of the involved herds.

The Nebraska child's ceftriaxone-resistant infection was not an isolated event. The percentage of non-Typhi *Salmonella* isolates in NARMS resistant to ceftriaxone increased over 20-fold from 0.1% in 1996 to 2% in 2001.¹¹ When patients from whom isolates were received in 1996–1998 were interviewed, few reported international travel, suggesting that most infections were domestically acquired.¹⁹ Furthermore, ceftriaxone resistance in most domestically acquired infections, including the infection in the child in Nebraska, is due to a unique *AmpC*-type resistance gene (*CMY-2*), which resides on a plasmid.^{19,22} The finding of a similar molecular mechanism of resistance among different *Salmonella* strains supports horizontal dissemination of a resistance determinant.¹⁹ A 1999 study at the University of Iowa found multidrug-resistant, cephalosporin-resistant bovine, porcine, and human *Salmonella* isolates from the same geographic region. All human and animal resistant isolates encoded a *CMY-2 AmpC*-like gene.⁶¹

The emergence of multidrug-resistant *Salmonella* Typhimurium definitive type 104 (DT104) in the United States and the United Kingdom, which is resistant to ampicillin, chloramphenicol, streptomycin, sulfonamides, and tetracycline (ACSSuT), is an example of how a highly resistant clone of *Salmonella* has the ability to spread effectively among animals and then to humans. Described in 1998 by Glynn *et al.*, the emergence of *S. Typhimurium* DT104 in the United States can be traced back to as early as 1985.²⁶ The prevalence of Typhimurium isolates with the five-drug pattern of resistance increased from 0.6% in 1979–1980 to 34% in 1996.²⁶ This strain remains common; among Typhimurium isolates submitted to NARMS, the prevalence of the ACSSuT resistance pattern was 29% in 2001.¹¹

Another multidrug-resistant *Salmonella* that has emerged recently in the United States has been named MDR-*AmpC Salmonella* Newport. This multidrug-resistant strain is resistant to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole, and tetracycline (ACSSuT), and apparently has acquired the *CMY-2 AmpC*-like gene conferring additional resistance to cephalothin, amoxicillin-clavulanic acid, cefotaxime, and ceftiofur. Of *Salmonella* Newport isolates submitted to NARMS in 2001, a remarkable 25% are MDR-*AmpC S. Newport*.¹¹

Commensal bacteria

Pathogenic bacteria, such as *Campylobacter* and *Salmonella*, are not the only concern when considering antimicrobial resistance in bacteria with food animal reservoirs. Commensal bacteria, which are naturally occurring host flora, constitute an enormous potential reservoir of resistance genes for pathogenic bacteria. The prevalence of antibiotic resistance in the commensal bacteria of humans and animals is considered to be a good indicator of the selective pressure of antibiotic usage and reflects the potential for resistance in future infections.^{29,35,42}

Most resistant bacteria have mobile genetic elements such as R plasmids and transposons. As the reservoir of resistant commensal bacteria increases, the plasmid reservoir becomes larger and enables more frequent transfer of resistance to pathogenic bacteria including *Salmonella* and *Shigella*. *Escherichia coli*,

which is the predominant isolate of aerobic fecal flora in humans and most animals, has demonstrated its ability to transfer resistance genes to other species, including pathogenic bacteria.^{8,12,29,43,50,54}

Recent studies have shown an emerging resistance in *E. coli* to fluoroquinolones and third-generation cephalosporins. A study by Garau *et al.* demonstrated an increase in quinolone resistance among *E. coli* isolates in Spain from 9% to 17% over the course of 5 years. This study also showed a high prevalence of quinolone-resistant *E. coli* in healthy children and adults (26% and 24%, respectively) that could not be explained by previous use of quinolones. Animal testing from slaughterhouses in the area found a high rate of quinolone-resistant *E. coli* in swine and chickens (45% and 90%, respectively).⁵⁰ Winokur *et al.* found 16% of clinical *E. coli* isolates from cattle and swine and 1% of clinical human *E. coli* isolates collected in Iowa to be resistant to extended-spectrum cephalosporins. This study also identified identical *CMY-2* genes in resistant isolates from both humans and animals, suggesting transfer of the resistance gene between food animals and humans.⁶²

Other examples of animal-to-human transfer of resistant commensal bacteria are high-level gentamicin-resistant enterococci and quinupristin/dalfopristin-resistant *Enterococcus faecium*. In the United States, gentamicin is commonly used in chickens and turkeys for prevention of early chick mortality, occasionally used in swine for treatment, and seldom used in cattle. The molecular mechanism for resistance for high-level gentamicin-resistant enterococci isolates isolated from food animals on farms, meat and poultry purchased from grocery stores, and from human stool specimens were evaluated.¹⁸ Although much heterogeneity was evident, indistinguishable isolates were identified from food animals, meat and poultry, and humans, providing evidence of the spread of gentamicin-resistant enterococci from animals to humans through the food supply.

Quinupristin/dalfopristin (Synercid[®]) was approved for use in humans in 1999 for treatment of vancomycin-resistant *E. faecium* infections. However, virginiamycin, an analog of quinupristin/dalfopristin that is cross-resistant, has been used as a growth promoter in food animals in the United States since 1974.^{15,47} A study conducted by the CDC in 1998–1999, before the approval of Synercid[®] use in humans, found quinupristin/dalfopristin-resistant *E. faecium* on 58% of chickens purchased in grocery stores from four different states. Additionally, quinupristin/dalfopristin-resistant *E. faecium* was found in 1% of the stools from nonhospitalized people who submitted a stool specimen to clinical laboratories.³⁸ Similar data in Europe led the European Union to ban the subtherapeutic use of virginiamycin in food animals in 1998.⁵⁹ These findings suggest virginiamycin use in chickens has created a large reservoir of quinupristin/dalfopristin-resistant *E. faecium*. The high carriage of quinupristin/dalfopristin-resistant *E. faecium* on chickens in grocery stores, and the frequent handling of chicken from grocery stores by consumers, suggests that humans are commonly exposed to these resistant bacteria. The use of quinupristin/dalfopristin in humans for the treatment of vancomycin-resistant *E. faecium* and other serious infections may contribute additional selective pressure leading to an increased prevalence of quinupristin/dalfopristin resistance in humans.

CLINICAL IMPLICATIONS

Human health consequences of increasing antimicrobial resistance in foodborne bacteria include an increase in foodborne illnesses and an increase in number of treatment failures. Mechanisms for these human health consequences are well described in a recent review.⁷ Increased human infections of resistant foodborne pathogens occur as the prevalence of resistance increases and as humans are exposed to antimicrobial agents. Taking an antimicrobial may lower the infectious dose for *Salmonella* and potentially other foodborne bacteria, if the pathogen is resistant to that antimicrobial.⁹ Analyses of antimicrobial-resistant *Salmonella* outbreaks have demonstrated that previous exposure to antimicrobials can result in a larger number of cases than would have occurred if the outbreak had been caused by a sensitive strain.¹³ Bohnhoff *et al.* showed in the early 1960s that mice with an “undisturbed” normal intestinal flora have a *Salmonella* infectious dose of about 10⁶ organisms.⁹ When they “disturbed” the normal flora by administering streptomycin, the infectious dose for streptomycin-resistant *Salmonella* decreased to only 10 organisms. In *Salmonella* outbreaks, it has been observed that preceding, unrelated treatment with an antimicrobial can predispose humans to infection with resistant^{28,49,53} or susceptible *Salmonella*.⁴⁶ Similarly, in studies of sporadic salmonellosis, preceding treatment with an antimicrobial was a risk factor for a resistant infection compared to susceptible infections.^{34,37,48} Physicians should be aware that, as foodborne pathogens become increasingly resistant, treating patients with antimicrobials, regardless of the reason, increases the risk for that patient to develop a subsequent infection caused by resistant foodborne bacteria. The public health impact of this potentiation effect is more cases of illness and larger outbreaks.

In addition to causing more human illnesses, increasing antimicrobial resistance in foodborne pathogens may result in treatment failures if the foodborne pathogen is resistant to an antimicrobial used for treatment. As previously described, resistance is emerging to antimicrobials commonly used for treatment of serious *Salmonella* infections, that is, fluoroquinolones in adults and extended-spectrum cephalosporins in children. An example of probable treatment failures was recently described by researchers in Denmark, where a multidrug-resistant *S. Typhimurium* DT104 outbreak attributed to contaminated pork was traced back to a swine herd.⁴¹ The *Salmonella* isolates from humans and pork samples had decreased susceptibility to fluoroquinolones, and 2 patients who were treated with fluoroquinolones died. An official review of these deaths concluded that decreased susceptibility to fluoroquinolones was a contributing factor.

CONCLUSION

Given that there is an increasing prevalence of antimicrobial resistance and that this resistance has clinical implications, there is a need for mitigation efforts. Such actions will require collaborative efforts by several partners, including the farming, veterinary, medical, and public health communities. Enhanced surveillance is essential for evaluating and directing these efforts. There is a particular need to establish surveillance of antimicrobial usage in animals.

In the United States, collaborative federal actions to address antimicrobial resistance in agriculture are outlined in the Public Health Action Plan to Combat Antimicrobial Resistance, released in 2001 by an interagency task force.³¹ A high-priority action item in this plan is the initiation of surveillance of the quantities of antimicrobial agents used in food animals. The essentiality of surveillance of the quantities of antimicrobial agents used in food animals for interpreting surveillance of antimicrobial resistance and for focusing intervention efforts has been reiterated by several groups, including the World Health Organization.⁶⁷ Additional action items in the Public Health Action Plan include improved surveillance, research, and education, and, as a further top-priority item, refining and implementing the FDA's Framework Document. This Framework Document proposes a modified approval process for antimicrobials used in animals.³ It intends to ensure the human safety of antimicrobials used in animals by prioritizing these drugs according to their importance in human medicine. Additionally, it proposes to establish required mitigation actions with increasing resistance and to account for resistance developing from specific animal uses. Education of veterinarians regarding appropriate use of antibiotics has been promoted by the American Veterinary Medical Association (AVMA) with published guidelines for the therapeutic use of antibiotics.³

The widespread use of antimicrobial agents in food animals is associated with increasing antimicrobial resistance in foodborne pathogens, which subsequently may be transferred to humans. The transfer of these resistant bacteria or the genetic determinants for resistance causes adverse health consequences in humans by increasing the number of foodborne illnesses and increasing the potential for treatment failures. Similar conclusions have been reached by several independent groups in the United States, including the Alliance of Prudent Use of Antibiotics and the Institute of Medicine.^{4,5} To address this public health problem, overuse and misuse of antimicrobial agents in food animals and humans must be reduced. This will be accomplished by adherence to guidelines for therapeutic use of antimicrobial agents in food animals, and the discontinuation of use of antimicrobial agents with a human analog as growth promotants. Several European countries have already demonstrated the feasibility of such measures and the effectiveness of these interventions to combat antimicrobial resistance and reduce public health risks.

REFERENCES

1. Aarestrup, F.M., A.M. Seyfarth, H.D. Emborg, K. Pederson, et al. 2001. Effect of abolishment of the use of antimicrobial agents for growth promotion on occurrence of antimicrobial resistance in fecal enterococci from food animals in Denmark. *Antimicrob. Agents Chemother.* **45**:2054–2059.
2. Altekruse, S., N. Stern, P. Fields, and D. Swerdlow. 1999. *Campylobacter jejuni*—an emerging foodborne pathogen. *Emerg. Infect. Dis.* **5**:28–35.
3. American Veterinary Medical Association. *Judicious Therapeutic Use of Antimicrobials*. Available: <http://www.avma.org/scienact/jtua/jtua98.asp>.
4. Angulo, F.J., K.R. Johnson, R.V. Tauxe, et al. 2000. Origins and consequences of antimicrobial-resistant nontyphoidal *Salmonella* implications for the use of fluoroquinolones in food animals. *Microb. Drug Resist.* **6**:77–83.
5. Animal Health Institute (AHI). 2000. "Survey indicates most antibiotics used in animals are used for treating and preventing disease." Press release, February 14. Available: <http://www.ahi.org/news%20room/press%20release/2000/feb/antibiotic%20usage%20data.htm>.
6. Bager, F., F.M. Aarestrup, M. Madsen, and H.C. Wegener. 1999. Glycopeptide resistance in *Enterococcus faecium* from broilers and pigs following discontinued use of avoparcin. *Microb. Drug Resist. Mech. Epidemiol. Dis.* **5**:53–56.
7. Barza, M. 2002. Potential mechanisms of increased disease in humans from antimicrobial resistance in food animals. *Clin. Infect. Dis.* **34**(Suppl 3):S123–S125.
8. Berkowitz, F.E., and B. Mechock. 1995. Third generation cephalosporin-resistant Gram-negative bacilli in the feces of hospitalized children. *Pediatr. Infect. Dis. J.* **14**:97–100.
9. Bohnhoff, M., and C.P. Miller. 1962. Enhanced susceptibility to *Salmonella* infection in streptomycin-treated mice. *J. Infect. Dis.* **111**:117–127.
10. Centers for Disease Control and Prevention. NARMS 2000 Annual Report. Available: <http://www.cdc.gov/narms/annuals.htm>.
11. Centers for Disease Control and Prevention. NARMS 2001 Annual Report. Available: <http://www.cdc.gov/narms/annuals.htm>.
12. Chaslus-Dancla, E., J.L. Marte, C. Carlier, et al. 1986. Emergence of aminoglycoside 3-*N*-acetyltransferase IV in *Escherichia coli* and *Salmonella typhimurium* isolated from animals. *Antimicrob. Agents Chemother.* **29**:239–243.
13. Cohen, M.L., and R.V. Tauxe. 1986. Drug-resistant *Salmonella* in the United States: an epidemiological perspective. *Science* **234**:964–969.
14. Commission regulation of amending council directive 70/524/EEC concerning additives in feedingstuffs as regards withdrawal of the authorization of certain antibiotics. Document No.: VI/7767/98. European Commission, Brussels, Belgium.
15. Committee on Drug Use in Food Animals, Panel on Animal Health, Food Safety, and Public Health, Board on Agriculture, National Research Council. 1999. The use of drugs in food animals: benefits and risk. National Academy Press, Washington, D.C.
16. Crump, J., T.J. Barrett, J.T. Nelson, and F.J. Angulo. 2003. Reevaluating fluoroquinolone breakpoints for *Salmonella enterica* serotype Typhi and for non-Typhi salmonellae. *Clin. Infect. Dis.* **37**:75–81.
17. DANMAP 2000—consumption of antimicrobial agents and resistance to antimicrobial agents in bacteria from food animals, food and humans in Denmark: report from Statens Serum Institut, Danish Veterinary and Food Administration, Danish Medicines Agency and Danish Veterinary Laboratory, 2001. Available: <http://www.vetinst.dk/dk/Publikationer/Danmap/Danmap%202000.pdf>.
18. Donabedian, S.M., L.A. Thal, E. Hershberger, M.B. Perri, J.W. Chow, P. Bartlett, R. Jones, K. Joyce, S. Rossiter, K. Gay, J. Johnson, C. Mackinson, E. Debess, J. Madden, F. Angulo, and M.J. Zervos. 2003. Molecular characterization of gentamicin-resistant *Enterococci* in the United States: evidence of spread from animals to humans through food. *J. Clin. Microbiol.* **41**:1109–1113.
19. Dunne, E.F., P.D. Fey, P. Kludt, et al. 2000. Emergence of domestically acquired ceftriaxone-resistant *Salmonella* infections associated with *ampC* beta-lactamase. *J. Am. Med. Assn.* **284**:3151–3156.
20. Embrog, H., A.K. Ersboll, O.E. Heuer, and H.C. Wegener. 2001. The effect of discontinuing the use of antimicrobial growth promoters on the productivity in the Danish broiler production. *Prev. Vet. Med.* **50**:53–70.
21. FAAIR Scientific Advisory Panel. 2002. The need to improve antimicrobial use in agriculture: select findings and conclusions. *Clin. Infect. Dis.* **34** (Suppl 3):S73–S75.

22. Fey, P.D., T.J. Safranek, M.E. Rupp, *et al.* 2000. Ceftriaxone-resistant *Salmonella* infection acquired by a child from cattle. *N. Engl. J. Med.* **342**:1242–1249.
23. Food and Drug Administration–Center for Veterinary Medicine. A proposed framework for evaluating and assuring the human safety of the microbial effects of antimicrobial new animal drugs intended for use in food-producing animals. Available: <http://www.fda.gov/cvm/index/vmac/antimi18.html#statement>.
24. Food and Drug Administration–Center for Veterinary Medicine. Risk assessment of fluoroquinolone use in poultry. Available: http://www.fda.gov/cvm/antimicrobial/Risk_asses.htm.
25. Garau, J., M. Xercavins, M. Rodriguez-Carballeira, J.R. Gomez-Vera, I. Coll, D. Vidal, T. Llovet, and A. Ruiz-Bremon. 1999. Emergence and dissemination of quinolone-resistant *Escherichia coli* in the community. *Antimicrob. Agents Chemother.* **43**:2736–2741.
26. Glynn, M.K., C. Bopp, W. Dewitt, *et al.* 1998. Emergence of multidrug-resistant *Salmonella* Enterica serotype Typhimurium DT104 infections in the United States. *N. Engl. J. Med.* **338**:1333–1338.
27. Greko, C. 1999. Antibiotics as growth promoters. *Acta Vet. Scand. Suppl* **92**:87–100.
28. Holmberg, S.D., M.T. Osterholm, K.A. Senger, and M.L. Cohen. 1984. Drug-resistant *Salmonella* from animals fed antimicrobials. *N. Engl. J. Med.* **311**:617–622.
29. Hummel, R., H. Tschape, and W. Witte. 1986. Spread of plasmid-mediated nourseothricin resistance due to antibiotic use in animal husbandry. *J. Basic Microbiol.* **26**:461–466.
30. Institute of Medicine. 2003. Microbial threats to health: emergence, detection, and response. National Academies Press, Washington, DC. Available: <http://www.nap.edu>.
31. Interagency Task Force on Antimicrobial Resistance. A Public Health Action Plan to Combat Antimicrobial Resistance. Available: <http://www.cdc.gov/drugresistance/actionplan/html/index.htm>.
32. Khachatourians, G.G. 1998. Agricultural use of antibiotics and the evolution and transfer of antibiotic-resistant bacteria. *CMAJ* **159**:1129–1136.
33. Klare, I., D. Badstubner, C. Konstabel, G. Bohme, H. Claus, and W. Witte. 1999. Decreased incidence of VanA-type vancomycin-resistant enterococci isolated from poultry meat and fecal samples of humans in the community after discontinuation of avoparcin usage in animal husbandry. *Microb. Drug Resist.* **5**:45–52.
34. Lee, L.A., N.D. Puhr, E.K. Maloney, N.H. Bean, and R.V. Tauxe. 1994. Increase in antimicrobial-resistant *Salmonella* infections in the United States, 1989–1990. *J. Infect. Dis.* **170**:128–134.
35. Lester, S.C., M. del Pilar Pla, F. Wang, *et al.* 1990. The carriage of *Escherichia coli* resistant to antimicrobial agents by healthy children in Boston, in Caracas, Venezuela, and in Qin Pu, China. *N. Engl. J. Med.* **323**:285–289.
36. Levy, S.B. 1997. Antibiotic resistance: an ecological imbalance. In S.B. Levy, J. Goode, and D.J. Chadwick (eds.), *Antibiotic resistance: origins, evolution, selection, and spread*. John Wiley & Sons, New York, pp. 1–9.
37. MacDonald, K.L., M.L. Cohen, N.T. Hargrett-Bean, *et al.* 1987. Changes in antimicrobial resistance of *Salmonella* isolated from humans in the United States. *J. Am. Med. Assn.* **258**:1496–1499.
38. McDonald, L.C., S. Rossiter, C. Mackinson, *et al.* 2001. Quinupristin-dalfopristin-resistant *Enterococcus faecium* on chicken and in human stool specimens. *N. Engl. J. Med.* **345**:1155–1160.
39. Mellon, M., C. Benbrook, and K. Benbrook. 2001. Hogging it: estimates of antimicrobial abuse in livestock. Union of Concerned Scientists Publications, Cambridge.
40. Meng, J., and M.P. Doyle. 1998. Emerging and evolving microbial foodborne pathogens. *Bull. Inst. Pasteur* **96**:151–164.
41. Molbak, K., D.L. Baggesen, F.M. Aarestrup, *et al.* 1999. An outbreak of multi-drug resistant, quinolone-resistant *Salmonella* enterica serotype Typhimurium DT104. *N. Engl. J. Med.* **341**:1420–1425.
42. Murray, B.E. 1992. Problems and dilemmas of antimicrobial resistance. *Pharmacotherapy* **12**:86S–93S.
43. Nikolich, M.P., G. Hong, N.B. Shoemaker, *et al.* 1994. Evidence for natural horizontal transfer of *tetQ* between bacteria that normally colonize humans and bacteria that normally colonize livestock. *Appl. Environ. Microbiol.* **60**:3255–3260.
44. Oosterom, J. 1991. Epidemiological studies and proposed preventive measures in the fight against human Salmonellosis. *Int. J. Food Microbiol.* **12**:41–51.
45. Pantosti, A., M. Del Grosso, S. Tagliabue, A. Macri, and A. Caprioli. 1999. Decrease of vancomycin-resistant enterococci in poultry meat after avoparcin ban (letter). *Lancet* **354**:741–742.
46. Pavia, A.T., L.D. Shipman, J.G. Wells, *et al.* 1990. Epidemiologic evidence that prior antimicrobial exposure decreases resistance to infection by antimicrobial-sensitive *Salmonella*. *J. Infect. Dis.* **161**:255–260.
47. Rende-Fournier, R., R. Leclercq, M. Galimand, *et al.* 1993. Identification of the *satA* gene encoding a streptogramin A acetyltransferase in *Enterococcus faecium* BM4145. *Antimicrob. Agents Chemother.* **37**:2119–2125.
48. Riley, L.W., M.L. Cohen, J.E. Seals, *et al.* 1984. Importance of host factors in human salmonellosis caused by multiresistant strains of *Salmonella*. *J. Infect. Dis.* **149**:878–883.
49. Ryan, C.A., M.K. Nickels, N.T. Hargrett-Bean, *et al.* 1987. Massive outbreak of antimicrobial-resistant salmonellosis traced to pasteurized milk. *J. Am. Med. Assn.* **258**:3269–3274.
50. Shoemaker, N.B., G. Wang, and A.A. Salyers. 1992. Evidence for natural transfer of a tetracycline resistance gene between bacteria from the human colon and bacteria from the bovine rumen. *Appl. Environ. Microbiol.* **58**:1313–1320.
51. Smith, K.E., J.M. Besser, C.W. Hedberg, *et al.* 1999. Quinolone-resistant *Campylobacter jejuni* infections in Minnesota, 1992–1998. *N. Engl. J. Med.* **340**:1525–1532.
52. Sorensen, T.L., H.C. Wegener, and N. Frimodt-Moller. 2002. Resistant bacteria in retail meats and antimicrobial use in animals. *N. Engl. J. Med.* **346**:777–779.
53. Spika, J.S., S.H. Waterman, G.W. Soo Hoo, *et al.* 1987. Chloramphenicol-resistant *Salmonella* Newport traced through hamburger to dairy farms. *N. Engl. J. Med.* **316**:565–570.
54. Tauxe, R.V., T.R. Cavanagh, and M.L. Cohen. 1989. Interspecies gene transfer in vivo producing an outbreak of multiply resistant Shigellosis. *J. Infect. Dis.* **160**:1067–1070.
55. Tauxe, R. 1992. Epidemiology of *Campylobacter jejuni* infections in the United States and other industrialized nations. In I. Nanchamkin, M.J. Blaser, and L.S. Tompkins (eds.), *Campylobacter jejuni*: current status and future trends. American Society for Microbiology Press, Washington, D.C., pp. 9–19.
56. United States Department of Agriculture, Food Safety and Inspection Service, Science and Technology Microbiology Division, April 1996 Nationwide Broiler Chicken Microbiological Baseline Data Collection Program, July 1994–June 1995. Available: <http://www.fsis.usda.gov/OPHS/baseline/contents.htm>.
57. van den Bogaard, A.E., and E.E. Stobberingh. 1999. Antibiotic usage in animals: impact on bacterial resistance and public health. *Drugs* **58**:589–607.
58. van Den Bogaard, A.E., N. Bruinsma, and E.E. Stobberingh. 2000. The effect of banning avoparcin on VRE carriage in the Netherlands. *J. Antimicrob. Chemother.* **46**:146–147.
59. Wegener, H.C., F.M. Aarestrup, L.B. Jensen, *et al.* 1999. Use of antimicrobial growth promoters in food animals and *Enterococcus faecium* resistance to therapeutic antimicrobial drugs in Europe. *Emerg. Infect. Dis.* **5**:329–335.
60. Wierup, M. 1998. Preventive methods replace antibiotic growth promoters: ten years experience from Sweden. *APUA Newsletter* **16**:1–4.

61. Winokur, P.L., A. Brueggemann, D.L. DeSalvo, *et al.* 2000. Animal and human multidrug-resistant, cephalosporin-resistant *Salmonella* isolates expressing a plasmid-mediated CMY-2 AmpC beta-lactamase. *Antimicrob. Agents Chemother.* **44**:2777–2783.
62. Winokur, P.L., D.L. Vonstein, L.J. Hoffman, E.K. Uhlenhopp, and G.V. Doern. 2001. Evidence for transfer of CMY-2 AmpC β -Lactamase plasmids between *Escherichia coli* and *Salmonella* isolates from food animals and humans. *Antimicrob. Agents Chemother.* **45**:2716–2722.
63. Witte, W. 1998. Medical consequences of antibiotic use in agriculture. *Science* **279**:996–997.
64. World Health Organization. 1997. The Medical Impact of the Use of Antimicrobials in Food Animals: Report and Proceedings of a WHO Meeting. Berlin, Germany, October 13–17, 1997.
65. World Health Organization. 1999. Containing Antimicrobial Resistance: Review of the Literature and Report of a WHO Workshop on the Development of a Global Strategy for the Containment of Antimicrobial Resistance. Geneva, Switzerland, February 4–5, 1999.
66. World Health Organization. 2000. WHO Global Principles for the Containment of Antimicrobial Resistance in Animals Intended for Food: Report of a WHO Consultation. Geneva, Switzerland, June 5–9, 2000.
67. World Health Organization. 2001. Monitoring antimicrobial usage in food animals for the protection of human health: Report of a WHO consultation. Oslo, Norway, September 10–13, 2001.

Address reprint requests to:

Dr. Fred Angulo
Centers for Disease Control and Prevention
1600 Clifton Road
MS D-63, Atlanta, GA 30333

E-mail: fangulo@cdc.gov